Matthew P. Goetz, MD
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Related Items
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
What the Next Generation of Cancer Biomarkers May Involve
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
How MSI and TMB Factor into Current Biomarker Testing Panels
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Breast Cancer
Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
How Real-World Data Are Consolidating Our Knowledge Regarding Melanoma Treatment
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
The Greatest Challenges in Incorporating Biomarkers into Cancer Care
David Spigel, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer
David Spigel, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
Last modified: December 8, 2017